Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.84 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.84 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | RECQL | P46063 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | EGFR | P00533 | 1/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.84 |
| ▸ | FYN | P06241 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.84 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.84 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.84 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876266 | 1.00 | CYSLTR1 (0.84) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL10054300 | 1.00 | CYSLTR1 (0.84) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL5002328 | 0.94 | CYSLTR1 (0.84) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL5002327 | 0.94 | CYSLTR1 (0.84) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL5002330 | 0.94 | CYSLTR1 (0.84) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL13597389 | 0.94 | CYSLTR1 (0.83) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL12995888 | 0.93 | CYSLTR1 (0.82) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL13854394 | 0.92 | CYSLTR1 (0.81) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL14639925 | 0.92 | CYSLTR1 (0.83) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL | |
| SCHEMBL13806347 | 0.92 | CYSLTR1 (0.83) | CYSLTR1CYSLTR2CYP2C8MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374681-A1 | CONTROLLED RELEASE COMPOSITIONS FOR TREATMENT OF COGNITIVE, EMOTIONAL AND MENTAL AILMENTS AND DISORDERS | SCHULTZ JACK WILLIAM (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140087059-A1 | PHARMACEUTICAL COMPOSITION AND PROCESS FOR MONTELUKAST TABLETS | PHARMA PASS LLC (US) | 2014-03-27 | — | — | US | disclosed |
| US-8426599-B2 | Method for preparation of Montelukast acid in ionic liquid medium | HANMI SCIENCE CO., LTD (KR) | 2013-04-23 | — | — | US | disclosed |
| US-8217174-B2 | Method of preparing montelukast and intermediates used therein | HANMI HOLDINGS CO., LTD. (KR) | 2012-07-10 | — | — | US | disclosed |
| EP-1948611-B1 | Process for the preparation of a leukotriene antagonist and intermediates thereof | ESTEVE QUIMICA SA (ES) | 2012-05-23 | — | — | EP | disclosed |
| US-8178680-B2 | Process for the preparation of Montelukast and its pharmaceutically acceptable salts | MSN LABORATORIES LIMITED (IN) | 2012-05-15 | — | — | US | disclosed |
| US-8115004-B2 | Process for pure montelukast sodium through pure intermediates as well as amine salts | MSN LABORATORIES LIMITED (IN) | 2012-02-14 | — | — | US | disclosed |
| EP-2077996-B1 | PURIFICATION PROCESS OF MONTELUKAST AND ITS AMINE SALTS | ESTEVE QUIMICA SA (ES) | 2011-07-06 | — | — | EP | disclosed |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | HANMI PHARM. CO., LTD. (KR) | 2011-05-05 | — | — | US | disclosed |
| US-7829716-B2 | decyclization of {3-[(E)-2(7-chloro-2-quinolinyl)vinyl]phenyl}-4,5-dihydro-3H-benzo[c]thiepin-1-one by methylmagnesium halide with following conversion to montelukast | Synthon Pharmaceuticals, Inc. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7470687-B2 | Aryl oximes | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20080214822-A1 | Process For the Preparation of a Leukotriene Antagonist | MEDICHEM, S.A. (ES) | 2008-09-04 | — | — | US | disclosed |
| WO-2008017667-A1 | PROCESS FOR THE PURIFICATION OF MONTELUKAST | Esteve Química, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017669-A1 | PURIFICATION PROCESS OF MONTELUKAST AND ITS AMINE SALTS | ESTEVE QUÍMICA, S. A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| US-7312328-B2 | Benzoylpyridazines | MERCK PATENT GMBH (DE) | 2007-12-25 | — | — | US | disclosed |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CHEMAGIS LTD. (IL) | 2007-09-06 | — | — | US | disclosed |
| US-20070208177-A1 | Novel process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof | CHEMAGIS LTD. (IL) | 2007-09-06 | — | — | US | disclosed |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135480-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | LTC4S, LTA4H, CYSLTR1 | CYSLTR1 3/4885CYSLTR2 10/4885CYP2C8 773/4885 |
| US-20070135642-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CYP4A11, CYP51A1, CYP4F11 | CYSLTR1 9/4885CYSLTR2 19/4885CYP2C8 382/4885 |
| US-20070135643-A1 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | CMA1, CYP51A1, NOTUM | CYSLTR1 5/4885CYSLTR2 11/4885CYP2C8 792/4885 |
| US-20140087059-A1 | PHARMACEUTICAL COMPOSITION AND PROCESS FOR MONTELUKAST TABLETS | CMA1, MASTL, MAST3 | CYSLTR1 19/4885CYSLTR2 36/4885CYP2C8 2423/4885 |
| US-20150374681-A1 | CONTROLLED RELEASE COMPOSITIONS FOR TREATMENT OF COGNITIVE, EMOTIONAL AND MENTAL AILMENTS AND DISORDERS | CYSLTR1, CYSLTR2, GRIK2 | CYSLTR1 1/4885CYSLTR2 2/4885CYP2C8 2503/4885 |
| US-20070208178-A1 | Reacting the side-chain precursor 1-(mercaptomethyl)cyclopropaneacetic acid (not an ester) with 2-(2-(3S)-(3-(7-chloro-2-quinolinyl)-vinylphenyl)-3-(methanesulfonyloxypropyl)phenyl-2-propanol in a basic solvent mixture; forming an amine salt; and exchanging the amine cation with sodium; 99.5+% pure | CYSLTR2, MPST, CMA1 | CYSLTR1 4/4885CYSLTR2 1/4885CYP2C8 1092/4885 |
| US-20070208177-A1 | Novel process for preparing 1-(mercaptomethyl)cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof | CMA1, CYSLTR1, MPST | CYSLTR1 2/4885CYSLTR2 5/4885CYP2C8 1018/4885 |
| US-20080214822-A1 | Process For the Preparation of a Leukotriene Antagonist | LTB4R2, LTC4S, LTB4R | CYSLTR1 5/4885CYSLTR2 6/4885CYP2C8 1985/4885 |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | CYSLTR1, LTC4S, CYSLTR2 | CYSLTR1 1/4885CYSLTR2 3/4885CYP2C8 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.